UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2022

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Attached hereto and incorporated by reference herein is the following exhibit:

99.1Lavie Bio Investor Presentation.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: February 14, 2022

By: /s/ Dorit Kreiner Dorit Kreiner Chief Financial Officer

Forward looking statement

This presentation contains "forward-looking to future events, and Lavie Bio (the "Company") and its parent, Evogene Ltd. ("Evgene"), may from time to time make other statements, regarding for uture financial or operating results and or other maters regarding or affecting us hat are considered "forward-looking statements" as defines Litigation Reform Act of 1995 the "PSLR4") and other securities laws, as anended. Statements that are not statements of his may be deemed to be forward-looking statements may be identified by the use of such words as "believe", "expect", "should", "planned", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation we divers, product pipeline, future sales, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are may affect the Company's actual results and coults to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our cirnitation, those described in greater detal in Evogene's Annual Report on Form 20-F and in other internes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Exept as required by applicable securities laws we obligation or commitment to update any information or to publicy release the results of any revisions to any be made to reflect future events or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospects or other of form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purches or securities of Evegene or the Company, nor shall the information or any part of the fact of its distribution form the basis of or be relied on in contract, commitment or reading thereto or to the securities of Evogene or the Company.

The trademarks included herein are the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

The Ag-Biologicals opportunity Driving healthier crops, sustainability and productive agriculture

The Ag-Biologicals

untapped potential

+ +++

+++ ++
+ +++
+++ +

ნ

Improve food quality, sustainability and agriculture productivity through microbiome based ag-biologicals technology and products

The Power of the Microbiome

Billions of microbes make a difference!

The challenge: Discovering the right microbes and tailoring them for commercial use

Biology Driven Design platform

The microbiome OS

් Lavie Bio holds an exclusive license to use Evogene for the discovery and development of products in Lavie Bio sheld of activity.

2 As part of Corteva's investment in Lavie Bio in 2019, Lavie acquired the assets of Taxon Biosciences, including a large microbial collection.

Decoding the natural diversity of genetic functionality Function-based product discovery & tailoring

Product DIDI DIDI DIDI DIDI Lead Optimized 1.189 Candidates Candidates + = Product Requirements Required Functions DIDI DIDAI DADA DIDI DIDAI DIDA DIDI DOLI DADA DIDI DADA DADA DIDI DIDI DADA Discovery Optimization Commercialization Microbiome Gene Pool of Function Catalog Min. Microbes Enhanced Maximized Max. Functions samples Microbiomes of Microbiome functionality functionality 10

Lavie Bio Next generation Ag-Biologicals

				lavie bio
		Crop Protection & Fertilizers	Ag-Biologicals Today	Ag-Biologicals Next generation
	Sustainability	+	++++	++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
	Efficacy	++++	++	++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
	Consistency	++++	+	1
œ	Commercial viability	++++	+	++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 11